Transient myeloproliferative disorder in children with Down syndrome.
Conditions
Interventions
Treatment will be advised when there is high MRD (above threshold) at week 8.
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: 1. All children with Down syndrome; 2. Age < 4 weeks; 3. If blasts are present in pleural or pericardial effusion, or in a liverbiopsy (in absence of blasts in peripheral blood); 4. Signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Children in whom the diagnosis Down syndrome can not be confirmed; 2. Complications that make sampling unwanted or impossible.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To determine the population-based frequency of TMD; 2. To establish and investigate the relation of TMD and ML-DS; 3. To see if treatment of TMD can prevent TMD-associated mortality and the development of ML-DS in later life. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To detect new genetic factors related to the progression of TMD to ML-DS; 2. To investigate the presence of lymphoid pre-leukemic clones in neonatal blood samples of TMD; 3. To describe the hematological abnormalities and clinical characteristics in patients with and without TMD. | — |
Contacts
Public ContactM. Blink
Dept of Paediatric Haematology/Oncology Erasmus MC- Sophia Children's Hospital POB 2060
Outcome results
None listed